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ABSTRACT
This article describes the evolution of the patenting of chemical
inventions in Spain over the past twenty years and examines
the roles played by Spanish and foreign firms. Spanish
chemical companies contribute significantly to overall business
R&D investment in Spain and are responsible for a large
share of all Spanish patent applications filed at the European
Patent Office. However in absolute terms the number of
chemical patents of Spanish origin is small compared to
those from other countries and Spanish firms are still far
behind their foreign counterparts in terms of patents with
legal effects in Spain granted by the European Patent Office.
Several reasons are advanced to explain why.
INTRODUCTION
Patents are increasingly used as indicators of a country’s
technological output, but the perceived benefits of patenting
vary significantly across sectors and patent propensity differs
across countries. Each industry must be considered in its
own context. Because process patents are generally not
considered as effective as product patents, secrecy may be
preferred in fields where process inventions are predominant
and some areas may require more protection than others,
but it is widely accepted that patents play an important role
in the chemical sector, notably for pharmaceuticals and
biotechnology (1-3). This article focuses on chemical
patents in Spain, a country with generally low
patenting rates that has experienced substantial
changes in the legal framework for the protection
of intellectual property since 1986, in particular
as regards chemical inventions. This was an
important year for Spain. It joined the European
Community, its patenting system was modified with
the signing of the European Patent Convention and
its current national patent law was enacted (4).
Spain’s patent law is based on the European
Convention model, but in order to protect the
domestic chemical industry from the potential arrival
of a flood of European chemical patents, it was
first drafted with a moratorium on the patentability
of chemical products. More precisely, Spain reserved
the right not to recognize any pharmaceutical or
chemical product patent until October 1992,
although it did accept the patentability of the
pharmaceutical and chemical procedures to obtain
or use these products. As a consequence, in theory,
no European patent protecting a pharmaceutical
or chemical product filed between 1986 and 1992
was valid in Spain. A chemical product patent
filed at the European Patent Office (EPO) in 1991
could thus be valid and enforceable in Germany
until 2011, but not so in Spain. In practice, however,
applicants would often draft their claims differently and
apply for protection in Spain only on the process to obtain
the chemical products, whereas elsewhere they would apply
for protection on the products themselves (5). 
The Spanish chemical industry is one of the most important
sectors of the Spanish economy. In 2007, it accounted for
10 percent of Spanish GDP and ranked first in business
investment in R&D, accounting for 25 percent of the total in
Spain. It is also an industry that has changed significantly
over the past decades. Firstly, there has been an important
shift in production and a move towards higher added value
segments where patent protection is considered more important.
Spain’s share of basic chemistry has decreased with respect
to total chemical production (it represented 61 percent in
1977, compared to only 42 percent in 2008), whereas the
shares of health-related chemistry and chemistry for industrial
and consumer uses have increased (19 percent and 20
percent in 1977 compared to 26 percent and 32 percent
in 2008, respectively). Furthermore, focus on international
markets has also increased, and the sector is now one of
Spain’s largest exporters, second only to the automotive
sector (the chemical sector exported 60 percent of its production
in 2008 compared to 50 percent in 2000). Spain also has
a number of its own multinationals and many leading foreign
chemical multinationals have offices in Spain, especially
pharmaceuticals, although as is the case with other sectors,
the Spanish chemical industry is predominantly made up of
small- and medium-sized enterprises (92 percent of the
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Figure 1. EPO Patent filings with Spanish applicants or Spanish inventors: all fields
v chemicals.
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3,500 firms employ less than 100 people) and has a large
number of micro-firms (54 percent employ less than 10
people) (6).
In this article we show how the chemical industry’s efforts
to increase output have in the past years led to higher patent
counts, taking into account that the current legal framework
on patents in Spain is still relatively young. In order to do
so, we focus on two types of patent indicators to obtain two
different results. Firstly, to illustrate the evolution of Spain as
a country producing chemical inventions seeking European-
wide patent protection, we examine patent applications filed
between 1978 and 2005 with the EPO. Data on European
patent applications filed by Spanish applicants or having
Spanish inventors was extracted from the September 2008
version of the European Patent Office Worldwide Database
on Patent Statistics (PATSTAT). Secondly, to determine the
evolution of Spain as country of destination of patented
chemical inventions owned by Spanish or foreign institutions,
we examine patents granted by the EPO and by the Spanish
Patent and Trademark Office (OEPM). We obtained data
on all types of patents valid in Spain
from OEPM patent databases and
restricted our analysis to those filed
between 1987 and 1999. To identify
patents in the chemical field we used
the OST-INPI/FhG-ISI classification,
which groups International Patent
Classification (IPC) codes into seven
broad technology areas and thirty
sub-areas. We considered chemical
patents as those having at least one
IPC code classified in the areas of
“chemistry-materials” or “pharmacy-
biotechnology” (7).
EUROPEAN PATENT
APPLICATIONS FOR
SPANISH CHEMICAL
INVENTIONS
To describe the evolution of the Spanish
chemical industry and public research
sector as producers of patented
inventions seeking validation in
European markets, we took all patent
applications filed with the EPO from
1978 to 2005 in which Spain
appeared as the country of the
applicants or of the inventors. The
European Patent Convention (EPC)
enables the patent applicant, by means
of a single procedure at EPO, to obtain
a patent in some or all of its 36
contracting states. Thus, if a patent
application is granted at EPO and
the applicant takes the necessary
steps to validate the grant in the
designated EPC states of his choice,
his invention will be protected by a
patent family formed by a number
of equivalent patents valid in different
countries. We counted the number
of patents with Spanish applicants to
assess how many inventions were
owned and controlled by Spanish
entities. The number of patents with
Spanish inventors was used to
determine the inventive capacity of
researchers and engineers resident
in Spain, regardless of whether inventions were controlled
by Spanish or foreign firms. 
In the country ranking of applicants for chemical patent
filings at the EPO, Spain holds the 18th position, accounting
for only 0.4 percent of the total of 499,209 applications
filed in the chemical field between 1978 and 2005. In turn,
Spain holds the 15th position in the country ranking of
inventors appearing in chemical patents at EPO, accounting
for 0.6 percent of the total. Most applications filed by Spanish
applicants were developed by Spanish inventors, but the
opposite does not hold. Applications for inventions developed
in Spain were also filed from foreign locations. Multinationals
with R&D laboratories based in Spain and foreign firms
cooperating with Spanish research centres often file patents
from their headquarters or IPR departments located abroad
rather than from their Spanish subsidiaries, a strategy also
observed for other countries. 
As shown in Figure 1, chemicals account for a large share
of all Spanish applications at the EPO. Between filing years
1992 and 2005, around 24 percent of all EPO filings with
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Spanish applicants were in the field of chemicals, roughly
the same share as the chemical sector´s contribution to total
business R&D expenditure in Spain. The share of chemicals
in EPO filings with Spanish inventors was higher (29 percent),
showing that the productivity of Spain in terms of chemical
patents is higher than what is indicated by patent counts
based solely on the origin of the applicant. Figure 1 also
reflects the rapid growth of EPO patent filings, in general
and in chemicals, especially since 1996 when Spain signed
the TRIPS agreement. The largest relative growth in EPO
patent applications was seen in pharmaceuticals and cosmetics,
which have gained importance over organic chemistry, the
second most important chemical area at present, consistently
with the shift in production towards health-related chemistry.
CHEMICAL PATENTS WITH LEGAL 
EFFECT IN SPAIN
To evaluate the attractiveness of Spanish chemical markets
for patented inventions, we examine patents with legal effects
in Spain. Basically, there are two types of patents valid in
Spain: those granted by the OEPM, and those granted by
the EPO that have been translated and validated in Spain.
PCT applications granted by OEPM would be the third type
of patents having legal effects in the Spanish territory, but
we leave them out of this analysis given their reduced number
(only 122 in the chemical field with filing years 1987-1999).
We focus on EPO and OEPM granted applications filed
between 1987 and 1999, that is, commencing with applications
filed a few months after the enactment of the patent law
(October 1986) and finalizing with those filed in 1999. This
time frame was applied to ensure that our study contained
information on all granted patents filed within this period,
regardless of their grant date, given that it can take three
to four years for a patent to be granted by the OEPM, and
even longer if filed at the EPO. 
Chemical patents account for a significant share of all patents
enforceable in Spain. Approximately 22 percent of all OEPM
granted patents filed between 1987 and 1999 came from
the chemical sector (5,878). The share of chemicals was
even higher for EPO patents. In fact, 41 percent of all EPO
patents with legal effects in Spain filed between 1987 and
1999 protect chemical inventions (72,109). Consistent with
the changes observed in the industry, both OEPM and EPO
patents have increased in pharmaceuticals-cosmetics with
respect to organic chemistry. The distribution between foreign
and Spanish applicants has been, however, quite different
for each type of patents. 
As shown in Figure 2, the annual rate of EPO chemical
patents valid in Spain granted to foreign applicants grew
rapidly between filing years 1987 and 1992, and then
remained roughly constant until 1999, with approximately
6,000 patents, compared to only around 20 held by Spanish
applicants every year. This confirms the attractiveness of
Spanish chemical markets internationally, where Spain is
the second highest overall consumer of pharmaceuticals of
all OECD countries, second to France and followed by the
United States (8). Although most of these patents are invented
abroad and owned by foreign applicants, mainly from United
States, Germany and Japan, the contribution of Spanish
inventors has increased over the years, both for Spanish
and foreign-owned patents. A total of 439 EPO patents filed
between 1987 and 1999 were invented in Spain, of which
206 were owned by Spanish applicants (87 percent of all
Spanish EPO patents) and 233 by foreign applicants (0.3
percent of all foreign EPO patents).
As for OEPM patents, whereas at the beginning of the period
foreign applicants held more than 500 per filing year, they
only had about 100 per year in the 1990s and have remained
at that level since then, reflecting the shift of foreign applicants
from OEPM to EPO after Spain joined the EPC. In contrast,
the number of OEPM patents owned by Spanish applicants
has been more or less constant during the whole period, at
a level slightly above of 200 per year. OEPM patents have
also become more domestic at the level of inventors, as more
than 90 percent of the Spanish OEPM patents filed between
1992 and 1999 had Spanish inventors, compared to only
about 4 percent of those having foreign applicants. Finally,
it is worth noting that the most spectacular growth has come
from Spanish universities and public research institutions,
who applied for 22 percent of all OEPM patents in 1999
compared to only 2 percent in 1987 (9). The Spanish public
research sector’s important contribution to patenting has
also been documented in a study on Spanish biotechnology
patents granted by the USPTO, indicating that this growth
is not restricted to national patents only (10). 
CONCLUSION
The patent statistics presented above show that approximately
one quarter of all Spanish applications to the European
Patent Office are filed to protect chemical inventions. This
Figure 2. Granted EPO and OEPM patents with legal effects in Spain in the field of chemicals.
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is consistent with the fact that the chemical industry is
responsible for approximately one quarter of all Spanish
business R&D. Nevertheless, in comparison with other
countries, Spain continues to have a low contribution to the
total number of EPO patent filings in the field of chemicals.
One possible explanation may be that not all inventive activity
in the Spanish chemical industry is, or even seeks to be,
protected by patents, another may be that the Spanish system
for the protection of chemical inventions is relatively recent
(with chemical and pharmaceutical products being patentable
only since 1992), but also structural reasons often attributed
to the Spanish national innovation system can be advanced,
such as a traditionally low propensity to invest in R&D and
patent in all sectors of the Spanish economy. Nevertheless,
the statistics show that the number of EPO filings with Spanish
inventors exceeds that of EPO filings with Spanish applicants,
so that some chemical inventions produced by researchers
in Spain, from the public or private sector, are filed from
abroad and thus escape official statistics on patent counts
based on the origin of applicants only.
Results also indicate, however, that the large majority of all
patents enforceable in Spain have not only been invented
abroad and are owned by foreign firms, but also that they
have been filed at EPO rather than at OEPM. Less than 1
percent of the 72,109 chemical patents with legal effects in
Spain that had been granted by EPO and filed between
1987 and 1999 had Spanish applicants (only 236), whereas
more than half of the 5,878 chemical patents granted by
OEPM and filed in the same period were owned by Spanish
applicants (3,040). Only a few of those owned by foreign
firms are invented in Spain, whereas most of the Spanish-
owned ones are national inventions, especially since 1992. 
The order of magnitude of the number of chemical patents
valid in Spain and owned by foreign applicants is much
higher than the number of those owned by Spanish applicants,
but the size of the Spanish chemical sector is small compared
to the chemical industry worldwide and Spain is reported
to be especially attractive for multinationals given its high
domestic consumption of pharmaceutical products, one of
the highest in the OECD. It is not surprising either to see that
foreign applicants prefer EPO to obtain patents having legal
effects in Spain (especially since 1992), as EPO enables
applicants to reach all EPC member countries (including
Spain) through a single procedure, and OEPM only gives
them access to the Spanish territory. Moreover, OEPM patents
are granted solely on the basis of formal requirements,
whereas EPO patents must undergo a substantive examination
(based on novelty, inventiveness and industrial application),
which means that EPO patents are stronger than those granted
by the OEPM. Since 2001, OEPM applicants can also choose
to have their patents undergo a substantive examination,
however, very few choose this alternative as it means increased
patent fees (except for universities, which are exempt of
OEPM patent fees also since 2001), the examination period
is substantially longer and there is a greater possibility of
rejection, as patent applications filed through the “general
procedure” at the OEPM are automatically granted provided
they are formally correct. Since 2004, approximately a total
of 200 OEPM applicants in all fields per year have chosen
this path, compared to the over 2,000 applicants opting for
the general procedure. 
In sum, Spanish applicants seeking patent protection on
chemical inventions only within Spain may continue to prefer
the cheaper and faster general procedure at OEPM, with
no substantial examination, but a growing number of Spanish
applicants file patents at EPO hoping to obtain stronger
patents with legal effects in different European countries, if
they are eventually granted. Investing in internationalization
and patent quality seems to be the right move in a context
where patents gain more importance as strategic tools, and
technological competition from foreign firms may become
even stronger, notably for pharmaceuticals and biotechnology.
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